

Clinical Trial Protocol

Iranian Registry of Clinical Trials

06 Jun 2026

A Phase III, randomized, two armed, parallel, double blind, active controlled, non-inferiority clinical trial to determine the non-inferior therapeutic efficacy and safety between Denosumab (60 mg, produced by AryoGen Pharmed) compared with Prolia® (60 mg, Denosumab, the reference drug, produced by Amgen Company) in improvement of bone mineral densitometry (BMD) among osteoporotic postmenopausal women

Protocol summary

Study aim

Assessment of non-inferiority effect of Denosumab (AryoGen Pharmed) compared with Prolia® (Denosumab, Amgen) in improvement of bone mineral densitometry (BMD) in lumbar spine (L1-L4), femoral neck and total hip among osteoporotic postmenopausal women during 18 months.

Design

190 patients with postmenopausal osteoporosis will be investigated via clinical test, bone densitometry, radiological evaluation, and medical examination, after signing the informed consent form, and if She holds all the inclusion criteria, the patient will be given a randomization code and will be allocated to one of the groups in a random fashion.

Settings and conduct

190 patients who fulfill the inclusion criteria will be given a randomization code and will be allocated to one of the two groups of the study receiving either Denosumab (AryoGen Pharmed) or Prolia (Amgen). During 18 months of follow up, each patient will receive 3 injections and will have 9 visits. Investigators, patients, and data analyzers will be unaware of the patient's grouping.

Participants/Inclusion and exclusion criteria

Postmenopausal women aged between 45 up to 75 with T-score equal to or less than -2.5 and equal to or more than -4 in femoral neck, total hip or Lumbar Spine L1-L4, or patients with high risk of fracture on the basis of FRAX criteria who need medicinal treatment according to osteoporosis treatment guidelines.

Intervention groups

Group I: Denosumab (AryoGen Pharmed™) prefilled syringe (60 mg/ml), SC injection every 6 months Group II:

Prolia (Amgen) prefilled syringe (60 mg/ml), SC injection every 6 months.

Main outcome variables

Assessment of the non-inferiority effect of Denosumab (AryoGen Pharmed) compared with Prolia® (Amgen) in the improvement of BMD in lumbar spines (L1-L4), femoral neck and total hip among osteoporotic postmenopausal women during 18 months.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT2017020521315N9**

Registration date: **2017-03-12, 1395/12/22**

Registration timing: **prospective**

Last update: **2018-10-02, 1397/07/10**

Update count: **2**

Registration date

2017-03-12, 1395/12/22

Registrant information

Name

Nassim Anjidani

Name of organization / entity

Orchid Pharmed

Country

Iran (Islamic Republic of)

Phone

+98 21 4347 3000

Email address

amini@orchidpharmed.com

Recruitment status**Recruitment complete****Funding source**

Aryogen Company

Expected recruitment start date

2017-04-21, 1396/02/01

Expected recruitment end date

2018-09-22, 1397/06/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

A Phase III, randomized, two armed, parallel, double blind, active controlled, non-inferiority clinical trial to determine the non-inferior therapeutic efficacy and safety between Denosumab (60 mg, produced by AryoGen Pharmed) compared with Prolia® (60 mg, Denosumab, the reference drug, produced by Amgen Company) in improvement of bone mineral densitometry (BMD) among osteoporotic postmenopausal women

Public title

Effect of denosumab administration (produced by Amgen or AryoGen Pharmed) in improvement of bone mineral densitometry (BMD) among osteoporotic postmenopausal women.

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Postmenopausal women aged between 45 up to 75. Bone mineral density T score at the lumbar spine (L1-L4), femoral neck or total hip should be equal or less than -2.5 and equal or more than -4. ($-4 \leq T \text{ score} \leq -2.5$); or patients with high risk of fracture on the basis of FRAX criteria which according to osteoporosis treatment guidelines, need medicinal treatment Ability to comprehend and willingness to sign the Informed Consent Form for this study; Signed informed consent with full knowledge and mental health.

Exclusion criteria:

Lack of consent for being in the trial and not complying with an 18-months follow-up. Having hypersensitivity to denosumab or any component in the formulation (excipients include acetic acid, sorbitol, Polysorbate 20, sodium hydroxide, water for injections) Malabsorption syndrome History of thyroid surgery, parathyroid surgery or intestinal resection which has been caused malabsorption Patient with CKD stage 4 and 5 should be excluded (GFR <30cc/min) Level of serum 25-(OH) vitamin D less than 20 ng/ml; (If vitamin deficiency has been corrected, and two tests show the level above 20 ng/ml within a month, the patient can be enrolled.) Pre-existing hypocalcemia (Albumin-adjusted serum calcium level less than 8 mg/dl in fasting specimens) which is uncorrectable Untreated hypercalciuria (>250 mg/24h) and hypocalciuria (<100 mg/24h). If urine calcium level of patient is less than 100 mg per 24 hours and by

vitamin D treatment the problem has been solved or if urine calcium level of patient is greater than 250 mg per 24 hours, but PTH is normal, the patient can be enrolled Presence of osteonecrosis of jaw (ONJ) risk factors including a diagnosis of cancer, poor oral hygiene, periodontal and/or dental diseases, having dentures; and comorbid disorders (anemia (hemoglobin level less than 11 g/dl, if it is corrected, patient can enter the study) history of diseases with coagulopathy, oral and dental infection) Malignancy Having severe and active infections; (Severe infection is a difficult treated infection, like diabetic foot infection, but if the infection is treatable, after treatment, the patient can be enrolled.) Being bed rest (for 2 weeks during the past 3 months) A case in which the patient cannot take 1000 mg oral elemental calcium per day; (as supplement) Conditions that influence bone metabolism, including hyperparathyroidism or hypoparathyroidism, hyperthyroidism or hypothyroidism, hypocalcemia, inflammatory rheumatologic diseases such as rheumatoid arthritis, Paget's disease of bone, osteomalacia that is resistant to therapy (definition of resistant to therapy: not being responder to 1-month administration of vitamin D) Patients will be excluded if they have one severe or more than 2 moderate vertebral fractures. (Severe fracture is defined as more than 50 percent vertebral height loss and moderate fracture is defined as 25-50 percent vertebral height loss). Use of injectable bisphosphonates within the previous 12 months Use of oral bisphosphonates within the previous 3 months History of severe skeletal pain with bisphosphonates Use of parathyroid hormone or its derivatives, systemic hormone-replacement therapy, selective estrogen-receptor modulator, calcitonin, or calcitriol within 6 weeks before study enrollment. Use of corticosteroids (>5 mg/prednisone daily or equivalent for ≥ 3 months), in the past 3 months and more Use of heparin (more than 20,000 international units/day for 6 months and longer), in the past 6 months and more. Patient that is possible to be administrated corticosteroids (>5 mg/prednisone daily or equivalent for ≥ 3 months) or heparin (more than 20,000 international units/day for 6 months and longer) in the 18 month of the study, because of her chronic disease(s) such as allergy, asthma, coagulation disorders, should be excluded.

AgeFrom **45 years** old to **75 years** old**Gender**

Female

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample size

Target sample size: **190**

Randomization (investigator's opinion)

Randomized

Randomization description

The randomization plan of the patients will be carried out centrally using an R-CRAN software version 3.2.3. Using permuted block randomization, blocks (length of each block is 4 or 2) will be made, for a total of 190 patients (with 1:1 allocation ratio). Once the randomization has been made, each patient is given a code with which she will be identified throughout the study. The assigned code will be made up of 3 numbers (corresponding to the randomization number) and by 4 initials (corresponding to the 2 first letter of the first name, the 2 first letter of the first surname) and 2 numbers (center code). The randomization number will be assigned in a consecutive way.

Blinding (investigator's opinion)

Double blinded

Blinding description

To prevent the influence of knowing intervention group on study conclusion, the subjects and those who assess the study outcomes will be unaware of the state of the patient with regard to receiving the active drugs or standard remedy. For this purpose, subjects and administrator of the drug will be blinded by using a similar masked prefilled syringes. All drugs packages will be identified by unique numbers

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Tehran university of medical science

Street address

First floor, NO 21, Dameshgh st, Felestin st. Keshavar Blv

City

Tehran

Province

Tehran

Postal code

411310

Approval date

2017-01-31, 1395/11/12

Ethics committee reference number

IR.TUMS.VCR.REC.1395.1588

2

Ethics committee

Name of ethics committee

Ethics committee of Tabriz university of medical science

Street address

School of medicine, Tabriz university of medical sciences, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

1561656

Approval date

2016-10-10, 1395/07/19

Ethics committee reference number

IR.TBZMED.REC.1395.758

Health conditions studied

1

Description of health condition studied

Postmenopausal osteoporosis

ICD-10 code

M80.0

ICD-10 code description

Postmenopausal osteoporosis

Primary outcomes

1

Description

Percentage change in BMD at the lumbar spine (L1-L4), femoral neck, and total hip

Timepoint

Baseline and at 18th month of the study

Method of measurement

BMD by dual-energy x-ray absorptiometry Hologic 4500 or higher

Secondary outcomes

1

Description

adverse events occurrence

Timepoint

all of the visit (1-9)

Method of measurement

Physical examination, physician Assessment, and laboratory tests

2

Description

Level of biochemical markers of bone metabolism (Serum CTX, Serum NTX, P1NP, OC, BSAP)

Timepoint

Before injection at visit 2, 3, 4, 5, 6, 7, 8 and 9

Method of measurement

ELISA method

3

Description

The incidence of new vertebral fracture

Timepoint

The incidence of new vertebral fracture at baseline and at 18th month of the study

Method of measurement

X-ray radiography

4

Description

Immunogenicity of two products

Timepoint

Before the injections, at visit 2, 5, 7 and 9

Method of measurement

ELISA method

Intervention groups

1

Description

Denosumab (produced by AryoGen Pharmed) prefilled syringe for patients with dose of 60 mg, subcutaneous (S/C) injection every 6 months, at the beginning of the trial, month 6 and 12.

Category

Treatment - Drugs

2

Description

Prolia® (produced by Amgen Company) prefilled syringe for patients with dose of 60 mg, subcutaneous (S/C) injection every 6 months, at the beginning of the trial, month 6 and 12.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Bone marrow Density center of Karaj

Full name of responsible person

Dr. Ahmad Salimzadeh, Dr. Gholam hossein Alishiri

Street address

Karaj Bone mineral density scan center, Yas building, Across Exchange building, Hafte-tir crossroads

City

Karaj

Province

Alborz

Postal code

416556332

Phone

+98 26 3271 5353

Email

salimzad@tums.ac.ir

2

Recruitment center

Name of recruitment center

Razi Hospital

Full name of responsible person

Dr. Asghar Haji Abasi

Street address

Razi Hospital, Sardar Jangal Av

City

Rasht

Province

Guilan

Postal code

2156323

Phone

+98 13 3354 1001

Email

hadjiabbasi.asghar@gmail.com

3

Recruitment center

Name of recruitment center

Alzahra Hospital

Full name of responsible person

Dr. Hadi Karimzadeh

Street address

Alzahra Hospital, Sofe Blvd, Keshvarz Highway, Isfahan

City

Isfahan

Province

Isfahan

Postal code

41448466

Phone

+98 31 3620 2020

Email

hadikarimzadeh28@gmail.com

4

Recruitment center

Name of recruitment center

Emam Reza hospital

Full name of responsible person

Dr. Mohammad Reza Hatf and Dr. Seyedeh Zahra Mirfeizi

Street address

Emam Reza hospital, Mashhad, Iran.

City

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Phone
+98 51 3854 3031
Email
mirfeiziz@mums.ac.ir

5

Recruitment center

Name of recruitment center
Sheykh Al-Raees Clinic
Full name of responsible person
Dr. Alireza Khabazi Oskouei
Street address
Sheykh Al-Raees Clinic, Azadi Blvd, Tabriz, Iran.
City
Tabriz
Province
East Azarbaijan
Postal code
143162313
Phone
+98 41 3336 6215
Email
Dr.khabazi@gmail.com

6

Recruitment center

Name of recruitment center
Hafez Hospital
Full name of responsible person
Dr. Mohammad Ali Nazariniya
Street address
Hafez Hospital, Chamran Blvd, Shiraz, Iran
City
Shiraz
Province
Fars
Postal code
71946-34786
Phone
+98 71 3627 1531
Email
nazariniam@gmail.com

7

Recruitment center

Name of recruitment center
Emam Reza hospital (501 Artesh)
Full name of responsible person
Dr. Mohsen Ghasemzadeh Soroush and Dr. Susan Ghasemzadeh Soroush
Street address
Emam Reza hospital (501 Artesh), Shahid Etemadzade St, west Fatemi AV, Tehran, Iran.
City
Tehran
Province
Tehran
Postal code
1564123
Phone

+98 21 8802 8350
Email
mohsensoroosh@gmail.com

8

Recruitment center

Name of recruitment center
Rheumatism center of Iran
Full name of responsible person
Dr. Farhad Gharibdoost, Dr.Mahdi Vojdanyan, Dr Ahmadreza Jamshidi
Street address
No.70, Khosravi Alley, North Kargar Av
City
Tehran
Province
Tehran
Postal code
16515656
Phone
+98 21 8800 5141
Email
vojdanian@gmail.com

9

Recruitment center

Name of recruitment center
Kasra Clinic
Full name of responsible person
Dr. Mehrdad Aghaee
Street address
Kasra Clinic, Edalat 22 St
City
Gorgan
Province
Golestan
Postal code
1461323
Phone
+98 17 3233 5574
Email
mehrdadaghaie@yahoo.com

10

Recruitment center

Name of recruitment center
Dr. Akbarian clinic
Full name of responsible person
Dr. Mahmoud Akbarian
Street address
Mir Emad Clinic, Mir Emad St, Beheshti Av
City
Tehran
Province
Tehran
Postal code
1256156165
Phone
+98 21 8875 3618
Email

makbarian@sina.tums.ac.ir

11

Recruitment center

Name of recruitment center

Rasool Akram Hospital

Full name of responsible person

Dr. Anoosheh Haghighi, Dr. Fatemeh Shirani

Street address

Rasool Akram Hospital, Mansouri St, Sattarkhan Av

City

Tehran

Province

Tehran

Postal code

65411656

Phone

+98 21 6435 1654

Email

shiranifa@gmail.com

12

Recruitment center

Name of recruitment center

Endocrinology and metabolism research center

Full name of responsible person

Dr. Gholamhossein Ranjbar Omrani

Street address

Endocrinology and metabolism research center, 3th floor, Namazi hospital, Zand St, Shiraz, Fars, Iran

City

Shiraz

Province

Fars

Postal code

71937-11351

Phone

+98 71 3628 1569

Fax

+98 71 3628 1569

Email

hormone@sums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

AryoGen Pharmed company

Full name of responsible person

Somayeh Amini

Street address

No.2, khorasani Alley, Derakhti Ave, dadman blvd, Shahrak-e-Gharb

City

Tehran

Province

Tehran

Postal code

1468813112

Phone

+98 21 4347 3000

Email

amini.s@orchidpharmed.com

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

AryoGen Pharmed company

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Orchid Pharmed company

Full name of responsible person

Ramin Azhdarzadeh

Position

Pharmacist (PhD), Clinical Trial Manager

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

No.2, khorasani Alley, Derakhti Ave, dadman blvd, Shahrak-e-Gharb

City

Tehran

Province

Tehran

Postal code

1468813112

Phone

+98 21 8808 8821

Fax**Email**

azhdarzadeh.m@orchidpharmed.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Rheumatology Research Center, Shariati Hospital.

Full name of responsible person

Ahmadreza Jamshidi

Position

Professor of Rheumatology

Latest degree

Ph.D.

Other areas of specialty/work

Internal Medicine

Street address

Shariati Hospital, Jalal Al Ahmad Highway, Tehran, Iran.

City

Tehran

Province

Tehran

Postal code

1411713137

Phone

+98 21 8800 5141

Fax

Email

jamshida@sina.tums.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Orchid Pharmed company

Full name of responsible person

Dr. Somayeh Amini

Position

Pharm.D./Medical Department Manager

Latest degree

Medical doctor

Other areas of specialty/work

Medical Pharmacy

Street address

No.2, khorasani Alley, Derakhti Ave, dadman blvd, Shahrak-e-Gharb

City

Tehran

Province

Tehran

Postal code

1468813112

Phone

+98 21 4347 3000

Fax

Email

amini.s@orchidpharmed.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

The company have no plan to do this

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available